Dongying Pharmaceutical's H-share full circulation has been approved by the China Securities Regulatory Commission. This allows 208 million domestic shares, representing 36.05% of the total share capital, to be converted into H-shares for listing. Following this approval, the company's tradable shares will significantly expand, increasing its market value in Hong Kong from HK$4.705 billion to HK$13.399 billion based on the closing price of the day. This expansion is expected to meet the thresholds for inclusion in Stock Connect and the Hang Seng Index. AI
RANK_REASON Company announcement regarding H-share full circulation approval and its impact on market value and index inclusion.
- China Securities Regulatory Commission
- Dongying Pharmaceutical
- Hang Seng Index
- H-share
- Stock Connect
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →